{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:17:06Z","timestamp":1787242626339,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pntd.0006527","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000}}],"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0006527","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T13:29:43Z","timestamp":1527254983000},"page":"e0006527","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-7770","authenticated-orcid":true,"given":"Charles","family":"Abongomera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermias","family":"Diro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7578-3626","authenticated-orcid":true,"given":"Alan","family":"de Lima Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefien","family":"Buyze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolja","family":"Stille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"van Griensven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert","family":"Ritmeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"HW Murray","year":"2005","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"F Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis Worldwide and Global Estimates of Its Incidence","volume":"7","author":"J Alvar","year":"2012","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4081\/gh.2013.88","article-title":"Identification of environmental parameters and risk mapping of visceral leishmaniasis in Ethiopia by using geographical information systems and a statistical approach","volume":"7","author":"T Tsegaw","year":"2013","journal-title":"Geospat Health"},{"key":"ref5","first-page":"287","article-title":"Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014","volume":"91","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e2869","DOI":"10.1371\/journal.pntd.0002869","article-title":"Visceral Leishmaniasis and HIV coinfection in East Africa","volume":"8","author":"E Diro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years","volume":"21","author":"J Alvar","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/cid\/cix607","article-title":"The Risk and Predictors of Visceral Leishmaniasis Relapse in Human Immunodeficiency Virus-Coinfected Patients in Ethiopia: A Retrospective Cohort Study","volume":"65","author":"C Abongomera","year":"2017","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e0004087","DOI":"10.1371\/journal.pntd.0004087","article-title":"Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study","volume":"9","author":"E Diro","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e1153","DOI":"10.1371\/journal.pntd.0001153","article-title":"Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review","volume":"5","author":"GF Cota","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/cid\/cix807","article-title":"Long-term Clinical Outcomes in Visceral Leishmaniasis\/Human Immunodeficiency Virus\u2014Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial","volume":"66","author":"E Diro","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4269\/ajtmh.1999.61.766","article-title":"High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients","volume":"61","author":"J Delgado","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00002030-199906180-00009","article-title":"Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B","volume":"13","author":"F Laguna","year":"1999","journal-title":"AIDS"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0035-9203(01)90110-5","article-title":"Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome","volume":"95","author":"K Ritmeijer","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/505217","article-title":"A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection","volume":"43","author":"K Ritmeijer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e2875","DOI":"10.1371\/journal.pntd.0002875","article-title":"High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia","volume":"8","author":"E Diro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40261-016-0481-0","article-title":"Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme","volume":"37","author":"R Kimutai","year":"2017","journal-title":"Clin Drug Investig"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e2195","DOI":"10.1371\/journal.pntd.0002195","article-title":"Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison","volume":"7","author":"GF Cota","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/510398","article-title":"HIV-1 Replication Is Stimulated by Sodium Stibogluconate, the Therapeutic Mainstay in the Treatment of Leishmaniasis","volume":"195","author":"C Barat","year":"2007","journal-title":"J Infect Dis"},{"key":"ref20","unstructured":"World Health Organization. Control of the leishmaniases. [Internet]. WHO Technical Report Series. 2010. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/iris\/bitstream\/10665\/44412\/1\/WHO_TRS_949_eng.pdf\" xlink:type=\"simple\">http:\/\/apps.who.int\/iris\/bitstream\/10665\/44412\/1\/WHO_TRS_949_eng.pdf<\/ext-link>"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"TPC Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2007.05.007","article-title":"Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo","volume":"30","author":"K Seifert","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","article-title":"Combination therapy for visceral leishmaniasis","volume":"10","author":"J van Griensven","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cid\/cir674","article-title":"Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence","volume":"53","author":"K Ritmeijer","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1046\/j.1365-3156.2001.00795.x","article-title":"A policy for leishmaniasis with respect to the prevention and control of drug resistance","volume":"6","author":"A Bryceson","year":"2001","journal-title":"Trop Med Int Heal"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"M Balasegaram","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4269\/ajtmh.2009.80.929","article-title":"Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia","volume":"80","author":"R ter Horst","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1128\/JCM.33.7.1742-1745.1995","article-title":"Leish-KIT, a stable direct agglutination test based on freeze-dried antigen for serodiagnosis of visceral leishmaniasis","volume":"33","author":"SEO Meredith","year":"1995","journal-title":"J Clin Microbiol"},{"key":"ref29","unstructured":"MSF. MSF Kala azar manual. 2016."},{"key":"ref30","unstructured":"Ministry of Health Federal Democratic Republic of Ethiopia. National Guidelines for Comprehensive HIV Prevention, Care and Treatment [Internet]. 2014. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/aidsfree.usaid.gov\/sites\/default\/files\/ethiopia_natl_gl_2014.pdf\" xlink:type=\"simple\">https:\/\/aidsfree.usaid.gov\/sites\/default\/files\/ethiopia_natl_gl_2014.pdf<\/ext-link>"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4269\/ajtmh.1983.32.475","article-title":"Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis","volume":"32","author":"JD Chulay","year":"1983","journal-title":"Am J Trop Med Hyg"},{"key":"ref32","article-title":"Treatment of tuberculosis: guidelines","year":"2010"},{"key":"ref33","unstructured":"World Health Organization. Interim WHO clinical staging of HIV\/AIDS and HIV\/AIDS case definitions for surveillance [Internet]. 2005. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/pub\/guidelines\/clinicalstaging.pdf?ua=1\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/pub\/guidelines\/clinicalstaging.pdf?ua=1<\/ext-link>"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1097\/QAD.0b013e32830007cd","article-title":"Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa","volume":"22","author":"SD Lawn","year":"2008","journal-title":"AIDS"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e0178996","DOI":"10.1371\/journal.pone.0178996","article-title":"Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia","volume":"12","author":"C Abongomera","year":"2017","journal-title":"PLoS One"},{"key":"ref36","first-page":"1317","article-title":"Prognosis and prognostic research: what, why, and how?","volume":"338","author":"KGM Moons","year":"2009","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e1674","DOI":"10.1371\/journal.pntd.0001674","article-title":"Sodium stibogluconate (SSG) &amp; paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6","author":"A Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: An open-label, non-inferiority, randomised controlled trial","volume":"377","author":"S Sundar","year":"2011","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/AAC.50.1.73-79.2006","article-title":"In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs","volume":"50","author":"K Seifert","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/civ530","article-title":"Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India","volume":"61","author":"R Mahajan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","article-title":"Leishmaniasis impact and treatment access","volume":"17","author":"M den Boer","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref42","article-title":"WHO | WHO and Gilead Sciences extend collaboration against visceral leishmaniasis","year":"2016"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","article-title":"Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?","volume":"2","author":"LH Freitas-Junior","year":"2012","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref44","unstructured":"Drugs for Neglected Diseases Initiative. Target Product Profile\u2014Visceral Leishmaniasis [Internet]. [cited 2017 Sep 24]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.dndi.org\/diseases-projects\/leishmaniasis\/tpp-vl\/\" xlink:type=\"simple\">http:\/\/www.dndi.org\/diseases-projects\/leishmaniasis\/tpp-vl\/<\/ext-link>"},{"key":"ref45","unstructured":"Drugs for Neglected Diseases Initiative. Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. [Internet]. [cited 2017 Aug 24]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02011958\" xlink:type=\"simple\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02011958<\/ext-link>"},{"key":"ref46","unstructured":"London School of Hygiene &amp; Tropical Medicine. A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in India [Internet]. [cited 2017 Aug 24]. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.londonntd.org\/research\/projects-search\/a-randomized-trial-of-ambisome-monotherapy-and-combination-of-ambisome\" xlink:type=\"simple\">http:\/\/www.londonntd.org\/research\/projects-search\/a-randomized-trial-of-ambisome-monotherapy-and-combination-of-ambisome<\/ext-link>"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trstmh.2006.02.005","article-title":"Unresponsiveness to AmBisome in some Sudanese patients with kala-azar","volume":"101","author":"M Mueller","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1128\/AAC.01298-10","article-title":"High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B","volume":"55","author":"F Chappuis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1086\/381203","article-title":"Conflict and Kala-Azar: Determinants of Adverse Outcomes of Kala-Azar among Patients in Southern Sudan","volume":"38","author":"S Collin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e1511","DOI":"10.1371\/journal.pntd.0001511","article-title":"Early clinical manifestations associated with death from visceral leishmaniasis","volume":"6","author":"VEM de Ara\u00fajo","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-3156.2009.02305.x","article-title":"Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda","volume":"14","author":"Y Mueller","year":"2009","journal-title":"Trop Med Int Health"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e2982","DOI":"10.1371\/journal.pntd.0002982","article-title":"Risk Factors for Adverse Prognosis and Death in American Visceral Leishmaniasis: A Meta-analysis","volume":"8","author":"VS Belo","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.7326\/0003-4819-124-7-199604010-00007","article-title":"Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources","volume":"124","author":"J Seaman","year":"1996","journal-title":"Ann Intern Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12288-010-0027-1","article-title":"Hematologic changes in visceral Leishmaniasis\/Kala Azar","volume":"26","author":"N Varma","year":"2010","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"e0005921","DOI":"10.1371\/journal.pntd.0005921","article-title":"A clinical severity scoring system for visceral leishmaniasis in immunocompetent patients in South Sudan","volume":"11","author":"SS K\u00e4mink","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00292-12","article-title":"Optimal dosing of miltefosine in children and adults with visceral leishmaniasis","volume":"56","author":"TPC Dorlo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/361058","article-title":"Bacterial Sepsis in Patients with Visceral Leishmaniasis in Northwest Ethiopia","volume":"2014","author":"M Endris","year":"2014","journal-title":"Biomed Res Int"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-3156.2010.02550.x","article-title":"Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia","volume":"15","author":"Z Hurissa","year":"2010","journal-title":"Trop Med Int Health"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0006527","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0006527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T09:12:44Z","timestamp":1604308364000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0006527"}},"subtitle":[],"editor":[{"given":"Waleed Saleh","family":"Al-Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":58,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0006527","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]}}}